IRB APPLICATION OF FDA REGULATIONS Click for Animation

Size: px
Start display at page:

Download "IRB APPLICATION OF FDA REGULATIONS Click for Animation"

Transcription

1 IRB APPLICATION OF FDA REGULATIONS Click for Animation Created 12/2016 Belinda Smith & Jennifer Hill, University of Kentucky Office of Research Integrity Acknowledgement Ada Sue Selwitz

2 FDA IRB Review & Informed Consent Regulations apply to 21 IRB Review with Relevant Expertise Informed Consent with FDA Required Elements & References Clinical Investigations with FDA Regulated Products

3 Some Clinical Investigations are also subject to FDA Investigational New Drug (IND) or Investigational Device Exemption (IDE) Regulations.

4 Sponsor-Investigator The Sponsor or Sponsor Investigator is responsible for complying with IND or IDE requirements which may involve submitting an IND or IDE application to FDA.

5 FDA requires an IRB to: evaluate investigator qualifications; assess adequacy of facilities; and question the need for an IND or IDE.

6 IRB interactive flowchart for identifying and applying FDA regulations to studies involving devices. Click Question Icon to link to FDA Guidance

7 Start Does study involve a Medical Device? If YES FDA Yes, study is testing the safety or effectiveness of a medical device. Is study a Clinical Investigation? No, device is being used to elicit a physiologic response or measure a clinical outcome and no safety or effectiveness data is being collected on the device itself. Not FDA Medical Device Investigational device not approved or cleared by FDA New use of a marketed device Component, part, accessory, battery In vitro device, assay or reagent Software or computer applications (e.g. MRI) Select Mobile Medical Application A homemade device Section 201(h) of the FD&C A Clinical Investigation Experiment in one or more human subjects; designed to evaluate the safety or effectiveness of a medical device in subjects, controls or specimens. 21 CFR Click for Guidance

8 Is study IDE Exempt? Yes, study meets exemption criteria 21 CFR 812.2c Ensure consent includes reference to FDA. If no greater than minimal risk, study may qualify for Expedited IRB Review Category 1 No Submit for Full IRB Review with sponsor s SR/NSR determination Examples of IDE Exempt Trials (must meet all applicable conditions) Study of device used in accord with FDA approved labeling and indications* and no intent to report to FDA in support of new indication or label change. An in vitro diagnostic device IF 4 criteria are met. Low risk studies that DO NOT collect data on safety or effectiveness (e.g., consumer preference, cosmetic modification). Device intended solely for veterinary or research animals. * Provide IRB with manufacturing information, labeling, instructions, warnings, or other material describing approved indications. Click for Guidance

9 IRB decides if SR or NSR NSR No IDE required (Abbreviated regulatory requirements apply) SR Sponsor submits IDE to FDA (ALL regulatory requirements apply) Unsure Sponsor contacts FDA for an SR/NSR determination Submit FDA IDE documentation Submit FDA Correspondence IRB Review Significant Risk (SR) presents a potential for serious risk to the health, safety, or welfare of a subject, or an implant, or designed to support or sustain human life, or substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health. Convened IRB considers device AS USED IN STUDY when making SR/NSR determination. NON Significant Risk (SR) Does NOT meet any criteria in significant risk definition. Involves a level of risk that doesn't warrant review by FDA; IRB acts as surrogate for FDA. Click for Guidance

10 IRB interactive flowchart for identifying and applying FDA regulations to studies involving drugs or biologics.

11 Start Does study involve a Drug or Biologic? If YES FDA Yes, drug use in study is outside course of medical practice. Is study a Clinical Investigation? No, use is in the course of medical practice or non drug product (e.g., supplement or E Cig) is not being used as a drug to treat, cure, or prevent a disease/condition. Not FDA Drug/Biologic Investigational drug not approved by FDA New indication for approved drug Other compounds intended to affect structure or function of the body (e.g., cosmetic) Dietary supplements, botanicals, probiotics, etc. if testing ability to diagnose, mitigate, treat or prevent disease. Vaccine, blood product, In Vitro Assay, other biologics Electronic Cigarettes used to treat/prevent addition Clinical Investigation Experiment in one or more human subjects; use of a drug in a study, other than the use of an approved drug in the course of medical practice. 21 CFR Click for Guidance

12 Is study IND Exempt? Yes, study meets exemption criteria 21 CFR 312.2c Ensure consent includes reference to FDA. If no greater than minimal risk, study may qualify for Expedited IRB Review Category 1 No Unsure Sponsor contacts FDA for an IND determination Submit FDA Correspondence Sponsor submits IND to FDA (ALL regulatory responsibilities apply) Submit FDA IND documentation IRB Review Examples of IND Exempt Trials Unapproved use of an approved drug if all criteria met: Lawfully marketed in US; No intent to report to FDA to support new indication; No intent to support change in labeling or advertising; Does not involve route of administration, dose, population that significantly increases risk or decreases tolerability; Conducted in compliance with FDA IRB review and informed consent regulations; and study is not intended to promote drug product. Dietary Supplement if study designed to: only to reduce risk of a disease; evaluate effect on structure or function of the body; or support a new or expanded health claim, and conducted in a population that does not include individuals less than 12 months old, those with altered immune systems, or those with serious or life threatening medical conditions. Click for Guidance